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Abstract
Background: Age-related macular degeneration (AMD) is a leading cause of blindness that affects the central
region of the retinal pigmented epithelium (RPE), choroid, and neural retina. Initially characterized by an
accumulation of sub-RPE deposits, AMD leads to progressive retinal degeneration, and in advanced cases,
irreversible vision loss. Although genetic analysis, animal models, and cell culture systems have yielded important
insights into AMD, the molecular pathways underlying AMD’s onset and progression remain poorly delineated. We
sought to better understand the molecular underpinnings of this devastating disease by performing the first
comparative transcriptome analysis of AMD and normal human donor eyes.
Methods: RPE-choroid and retina tissue samples were obtained from a common cohort of 31 normal, 26 AMD,
and 11 potential pre-AMD human donor eyes. Transcriptome profiles were generated for macular and extramacular
regions, and statistical and bioinformatic methods were employed to identify disease-associated gene signatures
and functionally enriched protein association networks. Selected genes of high significance were validated using
an independent donor cohort.
Results: We identified over 50 annotated genes enriched in cell-mediated immune responses that are globally
over-expressed in RPE-choroid AMD phenotypes. Using a machine learning model and a second donor cohort, we
show that the top 20 global genes are predictive of AMD clinical diagnosis. We also discovered functionally
enriched gene sets in the RPE-choroid that delineate the advanced AMD phenotypes, neovascular AMD and
geographic atrophy. Moreover, we identified a graded increase of transcript levels in the retina related to wound
response, complement cascade, and neurogenesis that strongly correlates with decreased levels of
phototransduction transcripts and increased AMD severity. Based on our findings, we assembled protein-protein
interactomes that highlight functional networks likely to be involved in AMD pathogenesis.
Conclusions: We discovered new global biomarkers and gene expression signatures of AMD. These results are
consistent with a model whereby cell-based inflammatory responses represent a central feature of AMD etiology,
and depending on genetics, environment, or stochastic factors, may give rise to the advanced AMD phenotypes
characterized by angiogenesis and/or cell death. Genes regulating these immunological activities, along with
numerous other genes identified here, represent promising new targets for AMD-directed therapeutics and
diagnostics.
Please see related commentary: http://www.biomedcentral.com/1741-7015/10/21/abstract
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The neural retina, retinal pigmented epithelium (RPE),
and choroid tissue complex is one of the most physiolo-
gically active tissues in humans and arguably our most
important sensory organ [1]. Perhaps due to its high
metabolic rate, unique vasculature system, and focused
exposure to light, this tissue complex, and in particular
the central macular region, is predisposed to degenera-
tion [2,3]. The age-related form of macular degeneration
(AMD) is the leading cause of irreversible blindness in
developed countries, and it is now estimated that 6.5%
of the US population, aged 40 years and older, have
AMD [4]. The most common AMD phenotype, gener-
ally termed ‘dry AMD’, is characterized by an increase
in the number and diameter of extracellular sub-RPE
deposits called drusen, pigmentary irregularities, pro-
gressive atrophy of the RPE and retina, and a graded
loss in visual acuity [5-10]. In advanced cases, AMD is
often associated with sub-retinal choroidal neovasculari-
zation (CNV; or ‘wet AMD’) and/or a clearly demar-
cated area of geographic atrophy (GA) in the macular
region of the RPE. Both advanced AMD phenotypes
cause severe vision loss.
Although aging is the prevailing risk factor for AMD,
environmental factors such as smoking or oxidative
stress may contribute to AMD’s occurrence and/or pro-
gression [11-14]. Moreover, genetic linkage analysis and
genome-wide association studies have identified a num-
ber of important genetic risk factors in recent years.
The discovery of genetic variants in complement factor
H, for example, firmly established a link between the
complement cascade and AMD biology [15-18]. Other
studies identified AMD risk variants in additional com-
plement-related genes (for example, C2, CFB, CFHR1/3,
C3) [19-22] as well as in a variety of non-complement-
related genes, including a locus of unknown functional
relevance (for example, ARMS2/HTRA1) [23-26] and
loci related to lipid metabolism (APOE, LIPC, ABCA1)
[27-33]. Despite these important discoveries, a detailed
view of the biological pathways that mediate AMD
development and progression has remained obscure.
Furthermore, due to the morphological diversity of
AMD clinical phenotypes, whether AMD represents a
single disease consisting of multiple phenotypes or a dis-
order composed of distinct macular diseases (for exam-
ple, dry AMD, CNV, and GA) is still unclear.
Compared to previous studies of AMD that have relied
upon indirect experimental systems (for example, animal
models, cell culture systems) and a reductionist experi-
mental approach, gene expression profiling of human
ocular tissues has great potential to more accurately and
comprehensively resolve AMD-associated molecular sig-
naling pathways. Coupled with a systems biology analysis,
t r a n s c r i p t o m ep r o f i l i n gc a nb eu s e df o rt h eu n b i a s e d
identification of gene co-expression modules, to build
molecular models with predictive utility, and to elucidate
functional networks [34,35]. Although several groups
have completed transcriptome-wide studies of relevance
to AMD, including the identification of macular and
extramacular differences in RPE-choroid gene expression,
RPE-specific expression signatures, and AMD-associated
changes in circulating leukocytes [36-40], no direct tran-
scriptome-wide analysis of human RPE-choroid and
retina AMD tissues has been reported to date.
Here we present our findings from a comparative tran-
scriptome analysis of ocular tissues derived from 68
human donor eyes, including 26 well-characterized AMD
eyes and 11 potential pre-AMD eyes. Our study identifies
cell-mediated immune responses as the central feature of
all AMD phenotypes, thus supporting the hypothesis that
AMD is a single disease with a common immunological
core process. In addition, in the RPE-choroid, we identi-
fied transcripts related to apoptosis and angiogenesis that
are over-expressed in GA and wet AMD, respectively. In
the retina, we observed a graded over-expression of
wound response, complement, and neurogenesis genes
that correlates with reduced levels of phototransduction
transcripts and increasingly advanced AMD phenotypes.
Finally, using these functionally enriched expression signa-
tures, we assembled two detailed interactomes that high-
light modular functional networks of classical dry AMD,
CNV, and GA in RPE-choroid and neural retina tissues.
These data provide new insights into the expression land-
scape of AMD pathophysiology, and reveal numerous new
targets for the development of AMD-directed pharmaceu-
ticals and diagnostics.
Methods
Donor eye tissue and RNA purification
RPE-choroid and retinal samples were isolated from
human donor eyes obtained from the University of Iowa
(GSH) and the Lions Eye Bank of Oregon. The Iowa eyes
were selected from a well-characterized repository derived
from over 3, 900 donors. Medical and ophthalmic his-
tories, a family questionnaire, blood, and sera were
obtained from the majority of donors. All Iowa donors
were independently classified by two retinal specialists
using gross pathologic features, and for 63 of the 68 Iowa
donors, fundus photographs were utilized for grading pur-
poses using well-established methods and morphological
criteria [5,41,42]. The combined analysis of the retinal spe-
cialists was adjudicated (GSH) and donors were placed
into groups based on the morphological phenotype of the
eye with the most advanced pathology. Table 1 provides
details of the grading scheme, and cross-references our
groupings with the AREDS and Rotterdam grades, where
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For each donor, only the eye with the most advanced phe-
notype (that is, the eye on which the classification was
based) was used for transcriptome analysis. Macular tre-
phine punches (8 mm) and temporally adjacent extrama-
cular trephine punches (6 mm) of the RPE-choroid and
retina were collected from Iowa eyes within 4 hours of
postmortem, flash frozen in liquid N2, and stored at -80°C.
Total DNA-free RNA was purified using a Qiagen RNeasy
miniprep and on-column DNA digestion according to the
methods of the manufacturer (Qiagen, Inc., Valencia, CA,
USA). The RPE-choroid isolation procedures and RNA
purification methods for material originating from the
Lions Eye Bank of Oregon are described in Radeke et al.
[36]. No retina samples were acquired from the Oregon
eyes. Unlike Iowa eyes, postmortem times for Oregon eyes
ranged up to 8.7 hours (90% > 4 hours), whole Oregon
eyes were stored in RNA stabilization buffer (RNAlater,
Ambion, Inc., Austin, TX, USA) at 4°C prior to sample
collection, and off-column DNA digestion was used. In
addition, unlike the Iowa eyes, which were expertly graded,
the Oregon eyes received only a general classification of
AMD based on medical histories confirmed by ophthal-
mological records. Oregon eyes with an absence of AMD
c l i n i c a lh i s t o r yw e r ec o n s i d e r e dn o r m a l .S i n c eO r e g o n
eyes received a less rigorous AMD classification than Iowa
eyes, the Oregon cohort was reserved for validation pur-
poses only. Donor specific details (for example, age, gen-
der, and AMD phenotype) can be accessed through the
Gene Expression Omnibus [GEO:GSE29801].
This study was reviewed and approved by the institu-
tional review boards at St Louis University, the University
of Iowa, the University of Utah, and the University of
California, Santa Barbara and conforms to the tenets of
the Declaration of Helsinki. Written informed consent
was obtained from all participants or surviving relatives.
Microarray hybridization, quantification, and
normalization
Global transcriptome profiling was carried out using the
Agilent Whole Human Genome 4 × 44 K in situ oligonu-
cleotide array platform (G4112F, Agilent Technologies,
Inc., Santa Clara, CA, USA) using the reagents and meth-
ods of the manufacturer, with the exception that ‘spike-in’
controls were not used. For the tissue samples, a two-
color universal reference experimental design was
employed where the dyes used to label experimental and
reference samples were alternated with each sample. The
universal reference was derived from a pool of donor eyes
and consisted of a 50:50 mixture of RPE-choroid and
retina RNA purified from tissue remaining after the macu-
lar and extramacular punches were removed. After Lowess
correction, background subtraction, and normalization
using the reference RNA, the net intensity was expressed
as a percentage of the sum of all signals times 100, 000
(Percentage of total × 100, 000). Detailed DNA microarray
methods and microarray data associated with this publica-
tion are available through the Gene Expression Omnibus
[GEO:GSE29801].
Identification of contaminating genes
To improve data quality and overall signal-to-noise ratio,
RPE-choroid and retina gene expression datasets were fil-
tered for the following putative contaminants: retina-
enriched genes in the RPE-choroid, RPE-choroid-enriched
genes in the retina, and gender-specific genes (for exam-
ple, XIST). Differentially expressed genes were determined
using an unpaired, two-sided Student’s t-test with unequal
variance, and the resulting P-values were adjusted by per-
muting class labels 1, 000 times with the Fisher-Yates
method [43]. Moreover, a false discovery rate (also,
q-value or Q) was determined for each gene probe using
the method of Storey and Tibshirani [44]. Unfiltered












Normal 1 0a No features of AMD 31
MD1 Pre-AMD 1 0b Hard macular drusen (< 63 μm) only 7
MD2 Sub-clinical
pre-AMD
2 1a Soft, distinct macular drusen (> 63 μm) 4 (1a only)
1b Macular pigmentary irregularities without soft drusen
Dry AMD Dry AMD
(non-GA)
3, 4b 2a Soft, indistinct (> 125 μm) or reticular macular drusen 17
2b Soft distinct macular drusen (> 63 μm) with pigmentary changes 17
3 Soft indistinct macular drusen with pigmentary changes 17
GA Geographic
atrophy
4a 4 Sharply demarcated area of apparent absence of the RPE (> 175 μm)
involving central macular region
2
CNV Wet AMD 4a 4 Sub-retinal choroidal neovascularization 4
GA/CNV 4a 4 Geographic atrophy with choroidal neovascularization 3
aNumber of Iowa cohort donors per AMD classification group.
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bined, quantile normalized [45], and log2 adjusted, and dif-
ferentially expressed genes between RPE-choroid and
retina with Q ≤ 0.02, permuted P ≤ 0.01, and fold change
≥ 1.5 were identified (Figure S1 in Additional file 1). Of 7,
029 RPE-choroid-enriched and 7, 736 retina-enriched
gene probes meeting these statistical criteria, those with
mean expression levels of < 100 (that is, approximately
6.64 in log2 space) in the opposing dataset were flagged as
contaminants. Genes with gender-specific expression dif-
ferences were identified using the combined RPE-choroid
and retina dataset, and all genes with Q ≤ 0.0001, per-
muted P ≤ 0.001, and fold change ≥ 1.5 were flagged as
gender-specific contaminants (21 male-enriched and 11
female-enriched gene probes).
Combinatorial class comparisons for disease gene
identification
Unfiltered RPE-choroid and retina datasets were quantile
normalized separately and log2 transformed. Gene probes
flagged as contaminants, or with minimal differential
expression across all arrays (sample variance ≤ 5), were
excluded from further analysis. Donor samples diagnosed
as GA/CNV (n = 3) were combined with the pure GA
(n =2 )a n dC N V( n = 4) samples to increase the n in
these categories. In addition, samples collected from one
43-year-old individual diagnosed with AMD were
excluded due to an atypically early disease onset. After
data preprocessing, all AMD/pre-AMD phenotypes (pre-
A M D( M D 1 ) ,s u b - c l i n i c a lp r e - A M D( M D 2 ) ,M D 1+
MD2 (MD), Dry AMD, GA, CNV), both separately and
combined (global), were tested for significant differential
expression against macular and/or extramacular age-
matched normal donor samples (≥ 60 years), for a total
of 21 two-class comparisons per gene probe per microar-
ray dataset (RPE-choroid and retina). Statistical methods
for differential expression analysis are described in ‘Iden-
tification of contaminating genes’.At a b l eo fa l lg e n e
probes with a permuted P <0 . 1a n df o l dc h a n g e≥ 1.5 is
provided as Table S1 in Additional file 2.
Identification of AMD disease modules
Differentially expressed genes (listed in Table S1 in Addi-
tional file 2) were organized into a matrix consisting of
the P-value for each gene (row i)a n dc l a s sc o m p a r i s o n
(column j). Each P-value was converted into a signifi-
cance score Sij, calculated as -Log10(Pij), and all scores
were assigned directionality based on the up- or down-
regulation of each disease gene (positive or negative,
respectively; non-significant genes have S =0 ) .G e n e
probes representing the same gene were collapsed by
averaging significance scores, resulting in a matrix con-
sisting of 42 columns (21 comparisons × 2 tissue types)
and 6, 479 rows (unique genes/probes). The matrix was
adjusted for AutoSOME clustering [46] using unit var-
iance normalization (columns) and sum of squares = 1
normalization (rows and columns). All rows were subse-
quently clustered with AutoSOME using 500 ensemble
runs, P < 0.005, and otherwise default parameters [46].
For each tissue type, clusters with genes primarily over-
or under-expressed in the same phenotype were com-
bined into larger groups termed ‘disease modules’.
Immunoglobulin gene probes
In one disease module (RPE-choroid Global Up), we
observed a number of immunoglobulin-related gene
probes along with many unannotated probes with highly
similar expression profiles. Using AutoSOME [46], all
gene probes with similar co-expression patterns to
k n o w nI Gp r o b e sw e r ei d e n t i f i e db yc l u s t e r i n gt h e
expression data from the Global Up module (cluster
parameters: P < 0.05, 500 ensemble runs, and otherwise
default parameters). BLAT searches of the human gen-
ome reference sequence using the UCSC Genome Web
Browser confirmed probe homology to IGJ,a sw e l la s
immunoglobulin heavy, kappa, and lambda chain
sequences. In total, 31 IG probes were found, and their
expression values were averaged in three figures to con-
serve space. The 31 individual probes are highlighted in
Figure S7 in Additional file 1.
Disease state prediction
To validate candidate AMD biomarkers, we used the
GenePattern implementation of support vector machine
(SVM) [47], a machine learning algorithm for sample
classification and prediction based on complex pattern
recognition. Iowa expression data were log2 transformed
and median-centered for the twenty most significant
genes from the RPE-choroid Global Up module. Using
known donor classifications (that is, Normal versus
AMD/pre-AMD), the expression data, with and without
age, were split into three training and test groups for
stratified three-fold cross-validation (SplitDatasetTrainT-
est: split method = cross-validation; folds = 3; otherwise
default parameters). SVM models were built for the
training data (using GenePattern default parameters),
and run on the corresponding test datasets, the full Ore-
gon dataset (expression data processed identically to
Iowa set), and a negative control consisting of rando-
mized Oregon data (20 random genes with and without
scrambled ages). Cross-validation accuracy was com-
puted as the total number of correct classifications from
all three Iowa test datasets divided by the number of
Iowa RPE-choroid array samples (n = 126). SVM classifi-
cation accuracy for the validation cohort (Oregon data)
was calculated as the average accuracy obtained using the
three SVM models. To calculate the statistical signifi-
cance for overall classifier performance on each dataset,
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by permuting class labels 10 million times, and a P-value
was determined as the fraction of randomized results
with a classification accuracy (averaged over the three
models) equal to or exceeding the original non-rando-
mized classification results [48]. P-values were also deter-
mined for individual SVMm o d e l su s i n gt h es a m e
approach without averaging classification results. Finally,
we note that our selection of the top 20 RPE-choroid
Global Up genes for this analysis was not arbitrary, but
was determined by iteratively running SVM (using cross-
validation) on all consecutive subsets of RPE-choroid
Global Up genes in the Iowa dataset, from the top single-
ton gene, to the top two genes, to the top three genes,
and so forth. Using gene expression data alone, the high-
est classification accuracy was achieved using the top 20
and 21 genes (identical results; data not shown).
Identification of disease modules enriched in protein-
protein associations
Each disease module was analyzed for statistical enrich-
ment of protein-protein associations using the STRING
v8.3 database [49] (default parameters). Importantly,
genes in GA&CNV Up/Down modules were not analyzed
independently, but were included in GA and CNV Up/
Down modules. Since STRING does not estimate statisti-
cal significance, as a proxy for enrichment, we used the
average node degree D, defined as 2 × Number of edges/
Number of nodes (edges = interactions; nodes = pro-
teins). Monte Carlo sampling was employed to estimate
the null distribution of D by sampling 50, 100, 200, 300,
and 400 randomly drawn proteins 10, 000 times from the
STRING database. Regression analysis revealed perfect
linear trends for expected node degree E(D)f o rP =0 . 0 5
(R
2 =1 ;E(D) = 0.0023 × nodes + 0.7318) and P =0 . 0 1
(R
2 =1 ;E(D) = 0.0022 × nodes + 0.9068), and for each P-
v a l u ew ed e t e r m i n e dE(D) given the actual number of
nodes within each disease module (that is, genes with
matching proteins in STRING). Figure S11 in Additional
file 1 illustrates the results of this analysis for the RPE-
choroid (Figure S11a) and retina (Figure S11b), expressed
as the deviation in node degree from random chance.
Assembly of RPE-choroid and retina AMD interactomes
To construct high-quality AMD interactomes, we inte-
grated both direct and indirect protein-protein interaction
(PPI) data from three sources: Ingenuity Pathway Analyzer
(IPA; Ingenuity Systems, Inc., Redwood City, CA, USA),
STRING v8.3 [49], and a curated human PPI dataset [50].
Redundant protein-protein associations were eliminated in
the final interactomes according to the following domi-
nance series: Bossi and Lehner PPI > IPA > STRING data-
base/experiment evidence > STRING text-mining
evidence. Thus, Bossi and Lehner PPI data were given pre-
cedence over all other PPI data sources.
RPE-choroid interactome
Three RPE-choroid disease modules (Global Up, CNV Up,
and GA Up) were found to have significant enrichment in
protein-protein associations (P < 0.01; Figure S11 in Addi-
tional file 1). We note that CNV Up and GA Up modules
include genes from the RPE-choroid GA&CNV Up mod-
ule. Using at most 70 nodes and only interactions derived
from Homo sapiens, an IPA Core Analysis was run for
each of the three disease modules. For inclusion in the
RPE-choroid interactome, we restricted IPA results to the
highest scoring IPA network for a given Core Analysis.
We also required a low ratio of predicted to observed pro-
teins/complexes. Using these criteria, Global Up and CNV
Up modules achieved high-quality networks. To reduce
IPA network complexity and thus improve human read-
ability, we eliminated self-edges as well as predicted pro-
teins unnecessary for linking disease module gene
products into the network. Additional interactions for
e a c hd i s e a s em o d u l ew e r ed e t e r m i n e du s i n gS T R I N G ,
with a minimum score of 0.7 (’high confidence’ score).
Since RPE-choroid GA Up is prominently enriched in
apoptosis, all STRING interactions among RPE-choroid
GA Up genes found in the ‘apoptosis’ Gene Ontology cate-
gory (determined using ToppFun [51]) were added. Addi-
tional interactions among CNV Up proteins were also
added by assembling a gene set consisting of CNV Up
genes found in the IPA network along with additional
CNV Up genes associated with the ‘Wnt signaling path-
way’ and ‘extracellular matrix’ functional enrichment cate-
gories (determined with DAVID [52]). STRING
interactions among CNV Up gene products derived from
experimental or database evidence (score ≥ 0.7) were pre-
ferentially added; however, interactions derived from
STRING text-mining (text score ≥ 0.7) were also added to
incorporate one remaining protein, FGF9. Given the abun-
dance of interactions identified by IPA for Global Up, no
STRING interactions were added to the Global Up sub-
network. Finally, interactions among all three disease
modules from the PPI dataset of Bossi and Lehner [50]
were added. The final RPE-choroid interactome was ren-
dered using Cytoscape 2.8.0 [53].
Retina interactome
Two retina disease modules, Global Up and CNV Up,
were found to be significantly enriched in protein asso-
ciations (P < 0.01; Figure S11 in Additional file 1). Given
the enrichment of retina CNV Down in phototransduc-
tion processes and the critical importance of phototrans-
duction to a perceptible disease phenotype, we also
analyzed retina CNV Down genes for inclusion in the
retina interactome. Notably, CNV Up and CNV Down
modules include genes from the retina GA&CNV Up and
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q u a l i t yc r i t e r i aa su s e df o rt h eR P E - c h o r o i d ,t h eI P A
Core Analysis did not yield high quality networks for any
of the three retina disease modules. Next, we used
STRING to identify protein-protein associations. Given
the large numbers of genes in retina CNV Up and Down
modules, we first isolated subsets of functionally enriched
genes from both modules using ToppFun [51]. Since
CNV Up is predominantly enriched in neural-related
processes, we isolated CNV Up genes found in the fol-
lowing Gene Ontology categories: neurogenesis, genera-
tion of neurons, neuron differentiation, and transmission
of nerve impulse. CNV Down genes associated with
vision were also isolated using the Gene Ontology cate-
gories: sensory perception of light stimulus, phototrans-
duction, and response to light stimulus. We included all
STRING interactions found within a combined gene set
consisting of all Global Up genes, neurogenesis-related
genes from CNV Up and vision-related genes from CNV
Down (we employed the default STRING score of 0.4
since a score of 0.7 resulted in 30% fewer connected pro-
teins). Finally, we added all human PPI data [50] deter-
mined for genes in the STRING-derived interactome.
The final retina interactome was rendered with Cytos-
cape 2.8.0 [53].
Compilation of AMD-associated genes
Through an extensive PubMed search and survey of recent
review articles, we assembled a large list of genes or gene
products with a confirmed or putative association with
AMD resulting from genetic linkage, expression differ-
ences (RNA or protein) or localization to drusen in
humans [15-33,40,54-110]. The gene list is provided in
Table S2 in Additional file 3. Rather than requiring valida-
tion in two or more studies, only a single reference of
association was required for inclusion in this list, to allow
for a more comprehensive collection. Fisher’se x a c tt e s t
was used to calculate the significance of overlap between
the 283 AMD-associated genes (HLA super-locus
excluded from count) in Table S2 in Additional file 3 and
the RPE-choroid and retina interactomes (83 and 92 total
differentially expressed network elements, respectively);
only annotated genes from the Agilent 4 × 44 k chipset




To investigate gene expression programs that character-
ize AMD, we assembled global transcriptome profiles of
macular and extramacular RPE-choroid and neural retina
tissues from normal and AMD human donor eyes. Of
two donor cohorts examined in this study, the Iowa
cohort consisted of 31 normal eyes and 37 atypical eyes
organized into the following graded phenotypes: macular
hard drusen (MD1), distinct macular soft drusen 65 to
125 μm without pigmentary abnormalities (MD2), dry
AMD without geographic atrophy (Dry AMD), wet AMD
(CNV), and dry AMD with geographic atrophy (GA) (see
Table 1 for detailed phenotype descriptions). The latter
three classes correspond to clinically recognized AMD
phenotypes while the former two classes, MD1 and MD2,
represent potential pre- or sub-clinical stages of AMD.
Although occasional hard drusen are common in the
adult population, elevated numbers of hard drusen, and
in particular macular hard drusen (that is, MD1), are not
common and have been associated with an increased risk
for developing AMD [111-114]. In addition, morphologi-
cal features of MD2 are classically associated with AMD,
but have not yet reached the size or extent necessary for
a clinical diagnosis. These two phenotypes were therefore
included in this study to explore potentially early events
leading to the development of clinical AMD. Unlike Iowa
eyes, donors from the second cohort were reserved for
validation purposes (Oregon eyes, n = 30, RPE-choroid
only). As a measure of quality control, we evaluated sam-
ples from both cohorts for postmortem RNA degrada-
tion, inter-array concordance, and agreement with
previously published transcriptome experiments
[36,38,115-117], and found our data to be of high quality
and suitable for genomics analysis (see Additional file 4
for a detailed discussion of sample and array quality con-
trol measures).
Employing an exhaustive series of pairwise class com-
parisons between age-matched normal donor samples (≥
60 years) and the five graded AMD/pre-AMD phenotypes
from the Iowa cohort, we identified numerous candidate
AMD-associated genes, all of which satisfy a minimum
fold change of 1.5 and permuted P-value cutoff of 0.1
(Table S1 in Additional file 2). Using a false discovery rate
of 10% to account for multiple hypothesis testing (that is,
Q ≤ 0.1), we found seven genes in the RPE-choroid that
exhibit differential expression across all AMD phenotypes,
regardless of macular or extramacular origin. Six of these
genes are expressed at higher levels in AMD (Figure 1),
including two genes (CXCL10 and CXCL9)t h a te n c o d e
angiostatic chemokines involved in leukocyte recruitment
and implicated in diverse pathologies [118]. Additional
genes found at higher levels include chromosome 10 open
reading frame 18 (C10orf18), ADP-ribosylation factor-like
9( ARL9; inferred from unannotated probe A_23_P58137,
see Figure S5 in Additional file 1 for evidence), frizzled
homolog 10 (FZD10), and cathepsin L2 (CTSL2). Only
one gene was found consistently expressed at lower levels
in the AMD RPE-choroid (gene probe A_24_P925565).
We also found four globally differentially expressed genes
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0.1 (three genes of increased abundance, LOC100294179,
HLA-A,a n dITGB1BP2, and one gene with lesser abun-
dance, GSTT1). Furthermore, using Q ≤ 0.1, most of the
gene expression changes associated with specific AMD
phenotypes were found in the sub-clinical AMD state
(that is, MD2), and for some disease phenotypes, no genes
showed differential expression (for example, CNV in RPE-
choroid).
Identification of AMD disease modules
Transcriptional heterogeneity in human donor eye tissue
can arise from multiple factors, including normal genetic
variation, environmental influences unrelated to AMD,
the presence of mixed cell types, and/or variable degrees
of AMD progression. Hence, the small number of candi-
date disease genes identified using Q ≤ 0.1 was not
unexpected. As an alternative approach, we relaxed the
differential expression threshold for individual genes,
and focused on identifying gene groups that exhibit
both coordinated expression in specific disease pheno-
types and significant functional enrichment in one or
more biological processes. In particular, the q-value
threshold was eliminated, and all differentially expressed
genes identified in the class comparison with permuted
P < 0.1 (Table S1 in Additional file 2) were clustered
based on significance scores using AutoSOME [46].
Resulting clusters were then analyzed for functional
enrichments. This approach, inspired by Segal et al.
[119], allows for the determination of gene expression
programs that may be obscured by noise. All clustering
results are illustrated in Figure S6 in Additional file 1
and the corresponding gene lists and data are provided
in Table S3 in Additional file 5. To highlight modularity,
clusters with genes differentially expressed in the same
disease phenotype(s) were further combined into AMD
disease modules, for both RPE-choroid (Figure 2a, left)
and retina (Figure 2b, left).
Elevated cellular immune response is associated with all
disease phenotypes
Although most of the 32 identified disease modules are
restricted to discrete AMD phenotypes (Figure 2, left),
four global disease modules were identified that consist
of genes differentially expressed in multiple AMD and
pre-AMD phenotypes (Figure 2a, b, right panels; also
Figure 1 RPE-choroid genes with significantly elevated transcript levels in AMD. Box plots of age-matched normal and AMD (including
pre-AMD) donor samples from the macular and extramacular RPE-choroid. All genes have a q-value ≤ 0.1 (false discovery rate ≤ 10%). Macular
and extramacular P-values were calculated using a one-sided Wilcoxon rank-sum test. ‘Expression’ denotes net intensity, as defined in Materials
and methods. Normal macula, n = 30; AMD macula, n = 35; Normal extramacula, n = 29; AMD extramacula, n = 32.
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Page 7 of 18Figure 2 Global and phenotype-specific AMD disease modules. (a, b) Disease-associated genes with permuted P-value < 0.1 and fold
difference ≥ 1.5 were clustered based on their significance score (see Materials and methods), and the results are displayed as heat maps for
RPE-choroid (a) and retina (b). Columns represent each disease phenotype, macula (Mac) and/or extramacula (XMac), and rows represent unique
genes/probes (gene symbols/Agilent ID). Global includes all AMD/pre-AMD phenotype classifications, and MD is composed of both MD1 and
MD2 donor samples. GA and CNV disease classes include GA/CNV donor samples. Disease modules are separated by horizontal lines and labeled
by higher or lower expression in one or more AMD/pre-AMD phenotypes (for example, ‘MD2 Up’, ‘GA Down’) compared to age-matched normal
donor samples. Global Up*/Global Down* disease modules enlarged on the right highlight individual genes with significant differential
expression in both macular and extramacular donor samples; for the entire list of Global Up/Down genes, see Figures S7 and S8 in Additional
file 1 and Table S3 in Additional file 5. Immunoglobulin probes are averaged to conserve space, as described in Materials and methods.
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Page 8 of 18see Figures S7 and S8 in Additional file 1). Among the
more than 50 array probes corresponding to annotated
genes in the RPE-choroid Global Up module, Gene
Ontology analysis revealed a striking enrichment in
genes regulating cell-mediated immune processes (for
example, chemokine activity, P =3 . 0×1 0
-11;T a b l eS 4
in Additional file 6). This module includes genes for all
known CXCR3 ligands (the previously identified CXCL9
and CXCL10 s h o w ni nF i g u r e1 ,a l o n gw i t hCXCL11);
CCL2, which encodes a pro-inflammatory chemokine
previously associated with AMD [64]; CD1D and CD86,
which are both associated with antigen presenting cells
[6,120,121]; and immunoglobulins (IGJ, IGH@, IGK@,
IGL@). Similarly, the Retina Global Up module is signif-
icantly enriched in inflammatory genes (P =1 . 3×1 0
-4).
However, unlike the RPE-choroid Global Up module,
these genes are involved in the complement and coagu-
lation cascades (C3, C4B, C1S, CFI, F5, SERPINA5;
Table S4 in Additional file 6). In contrast to Global Up
genes, Global Down genes are not functionally enriched,
aside from three neurofilament-associated genes in the
retina (NEFL, NEFM, PRPH), suggesting that AMD is
associated with a general down-regulation of genes
involved in diverse cellular processes. Notably, one gene
present in both RPE-choroid and Retina Global Down
modules, GSTT1 (glutathione S-transferase theta 1), is
known to play a protective role in RPE oxidative stress,
and reduced levels of this gene may be associated with
both advanced RPE aging [122] and AMD [85]. In sum-
mary, by examining clusters of co-expressed genes for
functional enrichment, these results greatly expand
upon the global disease genes previously identified using
Q ≤ 0.1 (Figure 1), and indicate that there are multiple
biomarkers of AMD. Furthermore, these data are consis-
tent with a global cellular immune response in AMD
pathogenesis.
Validation of RPE-choroid global signature genes using
an independent cohort
To validate our finding of a global AMD expression sig-
n a t u r e ,w eu s e daS V M[ 4 7 ]c lassifier applied to the
macular and extramacular expression profiles from the
top 20 genes in the RPE-choroid Global Up disease mod-
ule (Figure 3a). In addition to the set of donor samples
used in our initial transcriptome analysis (Iowa set), we
analyzed a validation cohort of RPE-choroid samples col-
lected from both normal eyes and eyes with a clinical
diagnosis of AMD obtained from the Lions Eye Bank of
Oregon. Using stratified three-fold cross-validation, we
trained SVM models on three different subsets of Iowa
RPE-choroid samples, and evaluated each model on the
remaining Iowa samples not used for training (one
unique test set for each model, n = 42), the full Oregon
dataset (n = 47), and a negative control Oregon dataset
(n = 47) composed of 20 randomly selected genes. More-
over, since age is the most prominent risk factor for
AMD, we also tested SVM performance with the inclu-
sion of donor age as a covariate.
All SVM models achieved statistically significant AMD
discrimination on every dataset except the randomized
negative control (Figures S9 and S10 in Additional file 1).
Based on the percentage of AMD donor samples that were
correctly identified, SVM models generated from expres-
sion data alone achieved a cross-validation classification
accuracy of 81% on the Iowa test data (P = 1.6 × 10
-5;F i g -
ure S9 in Additional file 1), an average classification accu-
racy of 71% on the Oregon dataset (P = 6.3 × 10
-4; Figure
S10a in Additional file 1), and an average accuracy of 55%
for 20 randomly selected Oregon genes (P =0 . 2 4 ;F i g u r e
S10b in Additional file 1). After incorporating age, the
cross-validation accuracy of the Iowa test data improved
to 84% (P =3 . 3×1 0
-7) and the average accuracy of the
Oregon data improved to 72% (P = 3.6 × 10
-4). It is worth
noting that the predictive accuracy of our SVM models
may be underestimated on the Oregon cohort due to pos-
sible non-diagnosis of AMD. For example, many of the
RPE-choroid Global Up diseasem o d u l et r a n s c r i p t sa r e
also found at elevated levels in what might be pre- or sub-
clinical stages of AMD (for example, MD1 and MD2; Fig-
ures 2a and 3a). Since most misclassified Oregon donors
represent the oldest individuals at highest risk for develop-
ing AMD (Figure 3b; Figure S10a in Additional file 1), and
because Oregon donors were not graded postmortem,
such individuals may have exhibited early stages of AMD.
Regardless, these data collectively validate our approach
for the identification of AMD-related genes, and demon-
strate that genes within the RPE-choroid Global Up dis-
ease module are global biomarkers of AMD.
Functional enrichments of AMD phenotype-specific
modules
In addition to Global Up modules, nearly three-quarters
of the remaining disease modules (19/26) have signifi-
cant functional enrichments (Table S4 in Additional file
6). Like the RPE-choroid Global Up module, inflamma-
tion is a prevalent functional category for other AMD
phenotype-specific RPE-choroid modules (pre-AMD
(MD1), Dry AMD, GA, and CNV Up), indicating that
distinct inflammatory elements may contribute to AMD
phenotypic diversity.
In particular, the two advanced AMD phenotypes, GA
and CNV, are highly enriched in functional pathways and
cellular activities. The RPE-choroid CNV Up module con-
tains numerous genes associated with vascularization,
including genes associated with extracellular matrix (P =
4.6 × 10
-7) and circulatory system development (P = 2.5 ×
10
-5). The RPE-choroid GA Up module is robustly
enriched in apoptotic processes (P = 9.6 × 10
-9), consistent
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graphic atrophy [79,123]. In retinal tissues, both CNV and
GA show elevated expression of major histocompatibility
complex I genes (P < 0.01) and genes involved in neuro-
genesis (P < 0.05), along with a concomitant decrease in
transcripts critical for photoreceptor function in the
macula (GA, P = 1.5 × 10
-4; CNV, P = 7.3 × 10
-9), includ-
ing red and green cone opsins (OPN1LW and OPN1MW)
previously associated with the degenerative effects of
drusen [124]. The Retina CNV Down module also
includes rhodopsin (RHO) and photoreceptor outer seg-
ment genes. Importantly, no evidence for elevated photo-
receptor transcript levels was seen in the corresponding
RPE-choroid samples, ruling out loss of photoreceptors
during dissection due to the presence of a disciform scar.
These data thus reaffirm the characteristic phenotypes of
these two advanced AMD phenotypes, and identify
numerous differentially expressed genes for further study.
Figure 3 Validation of global AMD signature genes with an independent cohort. Using a support vector machine (SVM) and the 20 most
significant genes in the RPE-choroid Global Up module (Figure 2a), a classification model for predicting AMD status was developed. (a)
Expression heat map (log2 scaled, median-centered) of the genes/probes from the Iowa donor set used to generate the classification model. All
donor ages are plotted under the heat map (yellow line indicates point at which donors become age-matched). (b) Results obtained using an
AMD SVM model that incorporates expression data and age to identify AMD donors in: a subset of the Iowa data that was not used for training
(that is, ‘Test Set’), the Oregon dataset (that is, ‘Validation Set’), and a randomized Oregon dataset (that is, ‘Random Genes and Ages’). These
results correspond to ‘SVM Model 2 (+Age)’, which is detailed along with other SVM models in Figures S9 and S10 in Additional file 1. Statistical
significance was determined as described in Materials and methods.
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and GA, our analysis did not reveal notable functional
features of Dry AMD (non-GA) in the RPE-choroid
beyond cell-mediated immune responses (Table S4 in
Additional file 6). Similarly, prominent phenotype-speci-
fic functional enrichment sw e r en o to b s e r v e di nt h e
retina, aside from a reduction of neuronal processes in
both MD2 and pooled samples of MD1 and MD2 (MD
Down). These results may reflect the heterogeneity of
classification systems applied to delineate putative stages
(or phenotypes) of MD1, MD2, and Dry AMD (Table 1).
Functional networks delineate global and advanced-stage
AMD phenotypes
As a first step toward developing a systems-level mole-
cular model of AMD, we examined the disease modules
for evidence of protein-protein associations. We found
six disease modules with significant enrichment in
known and predicted associations (P < 0.01; Figure S11
in Additional file 1). Further analysis of the three most
significant RPE-choroid modules (RPE-choroid Global,
CNV, and GA Up) revealed a protein interactome con-
sisting of both direct and indirect interactions among 95
proteins (83 disease module genes) divided into cell-
mediated immunity, angiogenesis/extracellular matrix
remodeling, and apoptosis subnetworks (Figure 4a). To
explore gene expression within this interactome across
each AMD and potential pre-AMD phenotype, normal-
ized expression levels from the macular RPE-choroid
were superimposed onto the network (Figure 4b) and
mean levels were plotted (Figure 4c). (Both macular and
extramacular expression levels, depicted as heat maps,
are shown in Figure S12 in Additional file 1.) As illu-
strated in Figure 4b, c, transcripts in the cell-mediated
immunity subnetwork are found at higher levels in the
macula for every phenotype, except MD2 (consistent
with Figure 2a, right). Furthermore, apoptosis and extra-
cellular matrix remodeling subnetwork transcripts are
more abundant in GA and CNV, respectively, consistent
with our previous results (Table S4 in Additional file 6).
Moreover, this interactome is strikingly enriched in
genes associated with AMD in prior literature (10/83
differential expressed network elements; P =3 . 3×1 0
-7).
A table of previously reported genes/gene products
cross-referenced with the interactome and disease mod-
ule genes is provided as Table S2 in Additional file 3
(see Materials and methods for details).
Separately, we assembled a retina interactome (Figure
5a) consisting of significantly connected proteins from
t h eG l o b a lU pa n dC N VU pm o d u l e s( P < 0.01; Figure
S11 in Additional file 1), along with phototransduction
proteins functionally enriched in the CNV Down module.
Normalized macular expression levels indicate a tight co-
regulation of complement/wound response and
neurogenesis subnetworks (Figure 5b, c; see Figure S13
in Additional file 1 for both macula and extramacula).
Furthermore, there is a progressive decrease of the
phototransduction subnetwork RNAs from Dry AMD to
GA to CNV that is virtually macula-specific (Figure S13
in Additional file 1). Finally, like the RPE-choroid, the
retina interactome significantly overlaps with previously
studied AMD genes/gene products (13/92 network ele-
ments; P =7 . 5×1 0
-10; Table S2 in Additional file 3).
These findings further validate our transcriptome data
and support the conventional classification of AMD into
functionally distinct and increasingly severe phenotypes.
Discussion
In this study, we analyzed transcriptome profiles of the tis-
sues most affected in AMD, the RPE-choroid and neural
retina. Using pairwise statistical analysis in combination
with significance score-based clustering, we identified 32
novel gene expression signatures, termed disease modules,
associated with major clinical AMD phenotypes as well as
two potential pre-AMD phenotypes (Figure 2). Among the
32 disease modules, we discovered 4 disease modules
common to multiple disease phenotypes (Figure 2). Next,
we showed by SVM analysis that expression levels of the
top 20 genes in the RPE-choroid Global Up module (Iowa
cohort) can significantly discriminate between clinically
documented cases of AMD and normal donors in an inde-
pendent RPE-choroid dataset (Oregon cohort). Finally,
using disease module genes with statistically enriched
functional concordance, we assembled detailed interac-
tomes that reveal both global and phenotype-specific pro-
cesses associated with AMD (Figures 4 and 5). Collectively
composed of nearly 200 differentially expressed genes,
these interactomes are statistically enriched in genes pre-
viously associated with AMD (23 total genes; Figures 4
and 5; Table S2 in Additional file 3), thus validating our
analytical strategy and further implicating the previously
unexplored network components in AMD pathology.
Our findings reveal that cell-based inflammatory
responses within the RPE-choroid are a core feature of
AMD. Remarkably, this global process is even detectable
in one of the earliest potential stages of the disease prior
to perceptible vision loss (MD1; Figures 4b and 5b).
Thus, Oregon donors classified by SVM models as AMD
(Figure S10a in Additional file 1), but initially labeled
‘normal’ (Materials and methods), may have been in the
beginning stages of AMD. Recently, elevated levels of
CXCL10 were reported in the sera and choroid of indivi-
duals with AMD [63], and elevated intraocular CCL2
levels were observed in neovascular AMD [64]. Here we
show that all AMD phenotypes in the RPE-choroid are
associated with elevated expression of all, or a subset, of
the following chemokines: CXCL1, CXCL2, CXCL9,
CXCL10, CXCL11, CCL2, and CCL8 (Figure 2a, right).
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Page 11 of 18Figure 4 RPE-choroid AMD interactome: globally conserved and phenotype-specific subnetworks. (a) AMD interactome showing direct
and indirect protein-protein interactions within RPE-choroid Global Up, CNV Up and GA Up disease modules assembled from three data sources:
STRING [49], Ingenuity Pathway Analyzer (IPA), and the Bossi and Lehner [50] human protein-protein interaction dataset (PPI) (see Materials and
methods). Gene products are represented by nodes, most of which are color-coded according to disease module. Yellow nodes represent genes
predicted by IPA, with the exception of VEGFA, which was predicted manually and is highly expressed in our RPE-choroid expression data.
Parallelogram-shaped nodes denote genes previously associated with AMD (Table S2 in Additional file 3). Individual immunoglobulin genes/
probes in the Global Up module were combined (see Materials and methods) and are represented as a single node (’Ig’). Exp, Db, and Text
indicate Experimental, Knowledge/Database, and Text-mining components of the STRING interaction score, respectively. (b) Heat maps depict
differential expression of network genes in the macula of each AMD/pre-AMD phenotype (also see Figure S12 in Additional file 1). Differential
expression was calculated as the geometric mean of each gene normalized to age-matched normal donor samples (≥ 60 years). Only pure GA
and CNV are represented. (For data including GA/CNV donor samples, see Figure S12 in Additional file 1). (c) Bar plot depicting mean of
expression data in (b), shown as a function of AMD/pre-AMD phenotype. Error bars represent standard error of the mean.
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dendritic cells, granulocytes, CD4+ Th1 cells, CD8+ T
cells, and natural killer cells to damaged tissue [125].
Although activated macrophages and other leukocytes
are known expressers, most of these chemokines are also
expressed in cultures of human fetal RPE following expo-
sure to IL1B [126]. (Notably, IL1B is found in the RPE-
choroid Global Up module.) Determining the cellular
source(s), context-specific cellular target(s), and regula-
tory mechanism(s) of AMD-associated chemokines
remains an important goal of future work.
A number of other factors in the RPE-choroid Global
Up module further implicate a cellular immune
response in AMD. For example, CD86 is expressed in
drusen-associated dendritic cells [6], CD69 is expressed
in activated leukocytes [127], and ILI41 and the elastoly-
tic protease CTSL2 are both expressed by macrophages
upon activation [128]. In addition, the up-regulation of
immunoglobulin genes supports an adaptive, autoim-
mune response in AMD that is consistent with previous
reports of immunoglobulins in drusen and drusen-asso-
ciated RPE [129] as well as anti-carboxyethylpyrrole
adduct antibodies [130] and anti-retinal antigen auto-
antibodies [131-133] in AMD sera.
We also identified a Retina Global Up module com-
posed of more than 50 genes common to sub-clinical
Figure 5 Retina AMD interactome shows graded expression across AMD phenotypes. (a) AMD interactome assembled from retina Global
Up, CNV Up and CNV Down disease modules assembled from three data sources: STRING [49], Ingenuity Pathway Analyzer (IPA), and the Bossi
and Lehner [50] human protein-protein interaction dataset (PPI) (see Materials and methods). Parallelogram-shaped nodes indicate genes
previously associated with AMD (Table S2 in Additional file 3). Exp, Db, and Text indicate Experimental, Knowledge/Database, and Text-mining
components of the STRING interaction score, respectively. (b) Heat maps depicting macular expression levels as a function of AMD and pre-AMD
phenotype (also see Figure S13 in Additional file 1). Expression levels were calculated as described in Figure 4. (c) Mean differential expression
for each subnetwork in (b), organized by AMD/pre-AMD phenotype. Error bars represent standard error of the mean.
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and GA, but not to donors at risk for AMD with macu-
lar hard drusen alone (MD1) with little to no vision loss
(Figure 2b, right, and Figure 5b). In addition to wound
response genes (for example, TGFB2, CYR61), this mod-
ule is highly enriched in complement genes previously
associated with AMD (C3, C4, C1S, CFI, SERPING1;
Table S4 in Additional file 6). Given the prevailing view
that the role of complement in AMD is linked to
deposition of the terminal complement complex in dru-
sen and the capillary pillars of the choroid [6-8,10], this
finding is unanticipated, and indicates a possible direct
role for complement in retinal degeneration. In addition,
the up-regulation of both complement and major histo-
compatibility complex I genes (HLA-A/B/C genes, and
B2M) in the Global Up module, along with APOE eleva-
tion in the Retina GA Up and CNV Up modules (Figure
5b) may reflect activation of resident microglia in the
retina [134,135]. This is further supported by reports of
a similar microglial immunological response in a
CX3CR1
-/- mouse model of AMD [135], as well as in
animal models of photo-induced retinal damage
[136,137].
Finally, by integrating functionally enriched gene sets
with interactome data, this work reveals many attractive
candidates for AMD therapeutics and diagnostics (Fig-
ures 4 and 5). Examples of wet AMD candidate targets
within the RPE-choroid interactome (Figure 4) include
IGF2, an imprinted gene adjacent to H19 (also in Figure
4) whose product up-regulates VEGF expression [138],
CYR61, a matricellular protein that modulates angiogen-
esis and apoptosis [139], and SPP1, a matricellular CFH
binding protein that is both a promoter of VEGF-
induced endothelial migration and an immunomodula-
tor [140,141]. GA Up genes with potential relevance for
pharmaceutical intervention include EPO, which inhibits
oxidative damage-induced apoptosis in cultured RPE
[142] and IL6, a mediator of RPE degeneration [143].
Furthermore, the interactome genes constitute only a
small subset of all identified disease module genes with
potential utility for AMD therapy. For example, 62
angiogenesis-related genes in the RPE-choroid CNV Up
module encode secreted proteins (Table S3 in Addi-
tional file 5), any one of which may represent an effec-
tive drug target.
Conclusions
In this study, we discovered novel global biomarkers,
phenotype-specific gene sets, and functional networks
associated with AMD. Although further studies will be
needed to elucidate the specific cell populations respon-
sible for gene expression changes in AMD, and to
further validate and confirm the identity of these AMD-
associated genes, our results represent a major step
toward assembling a systems-level model of AMD, and
establish a benchmark for future studies that incorpo-
rate both greater cohort sampling and higher-resolution
genomic profiling (for example, employing microdissec-
tion and next-generation sequencing methodologies).
Fundamentally, this work demonstrates that immune
responsiveness is a central, unifying process that charac-
terizes the molecular pathology of all AMD phenotypes
[6,7,10], consistent with the hypothesis that AMD is a
singular disease with multiple outcomes. In summary,
these data support the model that aging, environmental
stressors, and genetic predisposition all hasten the onset
and progression of cell-based immunological events,
leading to a state of chronic local inflammation that
mediates the development of the neovascular and/or
atrophic changes characteristic of advanced AMD. In
light of these results, we suggest that pharmaceuticals
targeting core immunological processes may have broad
efficacy for all clinical manifestations of AMD.
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